FDA approves Gwyn Lo, a low-dose estrogen contraceptive patch for women with BMI under 30.

The FDA has approved Gwyn Lo, a new once-weekly combined hormonal contraceptive patch with low-dose estrogen, designed for women with a BMI below 30. Developed by Viatris, Gwyn Lo offers a non-invasive, reversible birth control option delivering norelgestromin and ethinyl estradiol. Clinical trials showed effective contraception, good patch adhesion, and manageable side effects. The product is expected to be commercially available later in 2026, expanding contraceptive choices for women seeking low-estrogen options.